FDA okays Celgene’s Abraxane for pancreatic cancer

(Reuters) – U.S. regulators on Friday approved use of Celgene Corp’s Abraxane to treat patients with pancreatic cancer that has spread to other parts of the body, citing a trial that showed the drug significantly prolonged survival. The medicine is already approved in the United States to treat lung cancer and breast cancer. Celgene in January said Abraxane helped patients with advanced pancreatic cancer live an average of two months longer than those treated with chemotherapy, according to a late-stage study. …